The Centers for Medicare and Medicaid (CMS) recently added the revised Percent of Long-Stay Residents Who Received an Antipsychotic Medication measure to the iQIES MDS 3.0 Resident-Level Quality Measure (QM) report. This report may be run on demand in iQIES, allowing providers to review their measure calculations as part of their quality improvement efforts.
However, with the update an
issue has been identified in the MDS 3.0 Resident-Level Quality Measure (QM) Report where the footnote for the MDS Hybrid Measure Antipsychotic Med (L) is displaying the incorrect 3-month reporting period when an End Date after 09/30/2025 is requested.
Currently, if the requested End Date when running the report in iQIES is set to on or after 10/01/2025, then the report displays data for the latest available 3-month period which is Q3 2025 (07/01/2025 - 09/30/2025). When the issue is addressed, the footnote should correctly display the following: "The Percent of Long-Stay Residents Who Received an Antipsychotic Medication measure is calculated using MDS, Medicare and Medicaid claims and is based on 3 months of data (07/01/2025 - 09/30/2025)."
The expected resolution date posted by CMS is January 20, 2026.